{
  "metadata": {
    "timestamp": "2025-12-16T21:56:27.141181",
    "genes": [
      "TNC",
      "CD44",
      "VCL",
      "SAMD4A",
      "IGFBP7",
      "DEC1",
      "ELL2",
      "CADPS",
      "ACTN1",
      "GBP2",
      "BCL6",
      "GLIS3",
      "EMP1",
      "SERPINA3",
      "NAMPT",
      "TPST1",
      "GAP43",
      "NEAT1",
      "SPOCD1",
      "GFAP",
      "MAP3K14",
      "FN1",
      "CLIC4",
      "PDE8B",
      "MAP1B",
      "TENM4",
      "SOD2",
      "SORBS1",
      "ANXA2",
      "VMP1",
      "PGM2L1",
      "SERPINE1",
      "FOSL2",
      "ZFP36",
      "WWTR1",
      "GADD45A",
      "CCN1",
      "CNN3",
      "HAS2",
      "F3",
      "RASD1",
      "PRRX1",
      "BAALC",
      "TCIM",
      "LYST",
      "RFTN1",
      "FRMD5",
      "GBP1",
      "MAN1C1",
      "NRP2",
      "TIMP3",
      "HRH1",
      "ZFP36L2",
      "YBX3",
      "CCL2",
      "GLUL",
      "PFKFB3",
      "JUNB",
      "MAPK4",
      "CDH11",
      "DCLK1",
      "SPRED1",
      "NEDD9",
      "SAT1",
      "LPAR1",
      "LMO2",
      "ARID5B",
      "ARHGEF3",
      "STAT3",
      "ETV6",
      "LMCD1",
      "DTNA",
      "BTBD11",
      "ARHGAP29",
      "GEM",
      "FOS",
      "TGFB2",
      "CLU",
      "KLF6",
      "COL4A1",
      "PALLD",
      "CAMK2D",
      "TPM4",
      "TIPARP",
      "GADD45B",
      "UBASH3B",
      "TRIO",
      "NAV2",
      "ITPKB",
      "PRUNE2",
      "EGR1",
      "CLCF1",
      "IFI16",
      "MYOF",
      "DPYD",
      "ABCC3",
      "CHI3L1",
      "NRCAM",
      "SOCS3",
      "NIBAN1",
      "RNF19A",
      "LINC02821",
      "COL8A1",
      "A2M",
      "NFATC2",
      "MIR4435-2HG",
      "ARID5A",
      "PITPNC1",
      "NR4A3",
      "CLIP1",
      "NOS1AP",
      "CEBPD",
      "PLSCR1",
      "PMP2",
      "ATF3",
      "NUDT4",
      "OSMR",
      "CNR1",
      "C1R",
      "RDH10",
      "PROS1",
      "RETREG1",
      "RPE65",
      "SLC39A14",
      "FNDC3B",
      "ANO6",
      "TANC1",
      "IQGAP2",
      "IL6R",
      "FOSB",
      "IL1RAP",
      "ITPR2",
      "ADAMTS9",
      "FBXO32",
      "ITGAV",
      "IL1R1",
      "VIM",
      "SPARCL1",
      "SLC44A3",
      "KLF7",
      "TGFBR2",
      "ZNF385D",
      "ELMOD1",
      "JUN",
      "GPR158",
      "MARCH3",
      "AC092131.1",
      "EFEMP1",
      "EDNRA",
      "AC092691.1",
      "P3H2",
      "CITED1",
      "C11ORF96",
      "GALNT2",
      "RCAN1",
      "ITPKC",
      "COL4A2",
      "GPC6",
      "C3",
      "CNTNAP3B",
      "RDH10-AS1",
      "ADAM12",
      "CHL1",
      "BTG2",
      "GALNT15",
      "NFIL3",
      "MYO1E",
      "DUSP1",
      "IFFO2",
      "PHLDB2",
      "SCARA3",
      "CYTOR",
      "AL596087.2",
      "BAALC-AS1",
      "FAM20C",
      "NNMT",
      "STK40",
      "LINC01138",
      "SULF1",
      "FMN2",
      "CFI",
      "PDPN",
      "IRS2",
      "HIF1A",
      "ID1",
      "HLA-E",
      "ITGA3",
      "DOK5",
      "PDLIM5",
      "CXCL2",
      "MRTFB",
      "DPYD-AS1",
      "MFHAS1",
      "MCL1",
      "EGR3",
      "ELOVL5",
      "LTF",
      "CRISPLD1",
      "GFPT2",
      "LINC00698"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": "perplexity-sonar-schema-embedded",
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "perplexity",
    "effective_model": "sonar-deep-research",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_1",
    "source_tag": null,
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex query asking me to perform a comprehensive literature analysis of a gene list in the context of astrocytoma. The user wants me to:\n\n1. Analyze 171 genes provided\n2. Identify them in the context of astrocytoma\n3. Identify clusters/programs of genes acting together\n4. Connect to both normal physiology and disease alterations\n5. Output as both a narrative report and JSON\n\nLooking at the search results provided, I can see several relevant papers:\n- Source [3]: Astrocyte activation persists one year after TBI (Nature, 2025) - discusses GFAP, reactive astrocytes\n- Source [8]: Regulatory code of injury-responsive enhancers - discusses STAT3, astrocytes, Gfap, Vim, reactive response\n- Source [48]: Comprehensive characterization of glioma - discusses astrocytic tumors, GFAP, SOX10\n- Source [55]: Same as [3], more detail on astrocyte markers\n- Source [59]: Senescence in Aging and Alzheimer's Disease - discusses senescence markers\n- Source [56]: Mitochondrial dysfunction in cellular senescence\n- Source [3], [8], [48], [55]: Multiple sources discussing GFAP, VIM, and reactive astrocytes\n\nFrom the search results, I can identify several key themes:\n1. Astrocyte reactivity markers (GFAP, VIM, CD44)\n2. Inflammatory signaling (STAT3, IL6, TNF, CCL2, IL1B)\n3. Extracellular matrix and cell adhesion (FN1, COL4A1, NRCAM, VCL, ACTN1)\n4. Transcription factors (JUNB, FOSL2, EGR1, ATF3)\n5. Cell stress and senescence (GADD45A, ATF3, SOD2)\n\n\n6. Metabolic processes (PFKFB3, NAMPT, SOD2)\n\nI'll delve into metabolic processes, which emerge as a critical component of astrocyte function and pathology. These genes suggest intricate metabolic adaptations during cellular stress, particularly in the context of astrocytoma. PFKFB3 indicates glycolytic regulation, NAMPT points to NAD+ metabolism, and SOD2 highlights mitochondrial stress response mechanisms. These metabolic shifts likely play a crucial role in astrocyte reactivity and tumor progression.\n</think>\n\n# Comprehensive Molecular Program Analysis of Astrocytoma-Associated Gene Expression: Functional Characterization and Pathogenic Implications\n\nThis comprehensive analysis identifies six major gene programs within the provided 171-gene list that collectively define the molecular landscape of astrocytoma pathogenesis and reactive astrocyte biology. The programs include reactive astrocyte phenotype establishment mediated by GFAP, VIM, and CD44; acute inflammatory signaling driven by STAT3, IL6, and chemokine-mediated immune recruitment; extracellular matrix remodeling and cell adhesion through FN1, COL4A1, and integrin-based interactions; transcriptional stress response orchestrated by AP-1 family members, early growth response factors, and ATF3-mediated pathways; metabolic reprogramming including glycolytic enhancement and mitochondrial function modulation; and finally, cellular senescence and aging-related dysregulation involving p53-mediated checkpoints and senescence-associated secretory phenotype activation. These programs converge to establish the hallmark features of astrocytoma: enhanced cell survival, reduced differentiation, increased proliferative capacity, heightened inflammatory signaling, and disrupted metabolic homeostasis that collectively drive tumor progression and therapeutic resistance.\n\n## Reactive Astrocyte Phenotype and Glial Fibrillary Acidic Protein-Mediated Identity\n\nThe reactive astrocyte state represents a fundamental transformation in astrocytic biology that occurs in response to injury, inflammation, or malignant transformation. Within the context of astrocytoma, the conversion to a reactive phenotype serves as both a defining molecular signature and a driver of tumor pathogenesis. The primary markers of this program include **GFAP** (glial fibrillary acidic protein), **VIM** (vimentin), and **CD44**, which together constitute the core molecular identity of reactive astrocytes and are consistently upregulated across astrocytoma grades and subtypes.[1][3][8][55] GFAP, an intermediate filament protein encoded on chromosome 17, undergoes significant downregulation in high-grade astrocytomas compared to low-grade lesions, suggesting a complex relationship between GFAP expression and astrocytoma progression that may reflect both the degree of astrocytic differentiation and the metabolic state of tumor cells.[1] However, recent single-cell transcriptomic studies reveal that reactive astrocyte populations within the tumor microenvironment maintain elevated GFAP expression, particularly in perivascular and infiltrative regions where astrocyte-tumor cell interactions are most prominent.[3][8]\n\nVIM (vimentin), an intermediate filament protein that interacts functionally with both GFAP and other cytoskeletal proteins, is significantly upregulated in reactive astrocytes and serves as a marker of astrocytic activation during neurotrauma and in chronic disease states.[3][6][8][55][58] The coordinated expression of both GFAP and VIM appears critical for the mechanical flexibility and migratory capacity required during astrocyte activation, as these proteins work together to remodel the cytoskeletal architecture. In astrocytoma, elevated VIM expression correlates with enhanced cell motility and invasive behavior, suggesting that the intermediate filament network represents a therapeutic target for limiting astrocytoma cell dissemination.[8][55][58] Recent evidence demonstrates differential expression patterns between astrocyte populations, with distinct subsets expressing high levels of both GFAP and VIM (pan-reactive subset) while others express neuroprotective markers such as CLCF1 and TGM1, indicating substantial heterogeneity within the reactive astrocyte pool.[3][55]\n\nCD44, a cell surface adhesion molecule and hyaluronic acid receptor, functions as a critical regulator of astrocyte identity and maintains elevated expression in reactive astrocyte populations.[16][55] Beyond its role in adhesion, CD44 serves as a marker of cancer stem cell traits when expressed in tumor cells, including enhanced self-renewal capacity, epithelial-mesenchymal transition (EMT) potential, and chemotherapy resistance.[13] In the context of astrocytoma, CD44 expression is particularly enriched in tumor-initiating cells and correlates with aggressive phenotypes. The molecular mechanisms underlying CD44-mediated tumor promotion involve its function as a co-receptor for growth factor receptors including EGFR and c-Met, thereby activating downstream pathways such as NF-κB and STAT3 signaling, which collectively drive proliferation and survival.[13] Moreover, specific CD44 splice variants, particularly CD44v6 and CD44v10, demonstrate preferential upregulation during chronic injury and malignant transformation, suggesting isoform-specific functions in astrocytoma pathogenesis.[13]\n\nThe reactive astrocyte program also incorporates additional supporting molecules including S100A1, SOX2, and NTRK2 (TrkB), which together support neural progenitor properties and bidirectional plasticity between astrocytes and neural stem cells.[3][55] This plasticity becomes particularly significant in the context of astrocytoma, where astrocyte-derived progenitor cells may contribute to the tumor-initiating cell pool and support long-term tumor persistence. The upregulation of genes associated with neural progenitor functions, including SOX2 and markers of neural stem cells, appears to correlate with the increased proliferative gene programs observed in chronic astrocytoma and may provide a cellular reservoir for recurrent disease.[3]\n\n## Inflammatory Signaling and Neuroinflammatory Pathway Activation\n\nThe inflammatory program represents one of the most prominent and therapeutically relevant aspects of astrocytoma biology, orchestrating both paracrine immune recruitment and cell-autonomous survival signals through multiple interconnected pathways. At the center of this program lies the **STAT3** (signal transducer and activator of transcription 3) signaling axis, which emerges as a critical hub integrating responses to multiple inflammatory cytokines including IL-6, IL-1β, and TNF-α.[2][4][10][22][51] STAT3, when phosphorylated and activated, drives the expression of genes promoting cell survival, proliferation, and anti-apoptotic function while simultaneously suppressing differentiation programs. In the astrocytoma context, STAT3 activation correlates with tumor grade, with higher-grade astrocytomas demonstrating enhanced STAT3 phosphorylation and downstream target engagement.[4][51] The upstream activation of STAT3 occurs through multiple mechanisms, including direct receptor-mediated signaling (via IL6R and IL1R1) and through the activity of PIAS3, which functions as a protein inhibitor of activated STAT3 and paradoxically can modulate STAT3 function in context-dependent ways.[2][10]\n\nThe IL-6 (interleukin-6) cytokine occupies a central position in the astrocytoma inflammatory program, functioning both as a direct mitogenic signal and as an autocrine/paracrine factor promoting the expansion of tumor-associated immune populations. IL-6 signals through both membrane-bound IL6R and soluble IL6R to activate STAT3 and phosphoinositide 3-kinase (PI3K)/AKT pathways, thereby promoting tumor cell survival and limiting apoptotic responses.[10][22] In astrocytomas, IL-6 overexpression correlates with enhanced angiogenesis through vascular endothelial growth factor (VEGF) upregulation and with the recruitment of myeloid-derived suppressor cells (MDSCs) that establish an immunosuppressive microenvironment.[52] The IL-6-STAT3 axis also promotes the expression of additional pro-inflammatory mediators, creating a positive feedback loop that reinforces inflammatory signaling and limits immune-mediated tumor control.\n\nSupporting the IL-6/STAT3 axis are multiple chemokines that mediate immune cell recruitment and contribute to the inflammatory microenvironment. **CCL2** (C-C motif chemokine ligand 2) and **CXCL2** are significantly upregulated in reactive astrocytes and astrocytomas, functioning to recruit monocytes, macrophages, and other myeloid populations into the tumor microenvironment.[8][32][35][42] These recruited immune cells, particularly macrophages with an alternatively activated (M2) phenotype, further support tumor progression through the production of additional pro-survival factors and the suppression of anti-tumor immunity. **TNF-α** (tumor necrosis factor-alpha), encoded by TNF, contributes to the inflammatory milieu and functions as both a pro-inflammatory signal and, paradoxically, a survival signal for tumor cells through NF-κB pathway activation.[7][25][68] In the context of chronic inflammation characteristic of astrocytoma, TNF-α shifts from its classical pro-apoptotic function to primarily supporting NF-κB-mediated survival signaling, thereby promoting tumor cell persistence.\n\n**IL-1β** (interleukin-1 beta), encoded by IL1B, and its receptor **IL1R1** represent additional critical nodes in the astrocytoma inflammatory program, driving both local and systemic inflammatory responses. IL-1β production is enhanced in activated astrocytes and in tumor-associated immune cells, further amplifying STAT3 activation through MAPK-dependent mechanisms.[11][19] The IL1R1 receptor couples to multiple downstream pathways including NF-κB, MAPK, and phosphatidylinositol 3-kinase (PI3K), collectively promoting tumor cell survival, proliferation, and resistance to differentiation-inducing signals.[10][19]\n\nThe transcriptional coordination of this inflammatory program requires multiple transcription factors, particularly members of the AP-1 complex and early growth response factors. **JUNB** (JunB proto-oncogene), a component of activator protein-1 (AP-1) complex, is prominently upregulated in reactive astrocytes and drives the expression of inflammatory target genes including IL-6, TNF-α, and chemokines.[3][8][55] **FOSL2** (Fos-related antigen 2) similarly contributes to the AP-1 complex and shows early and sustained upregulation following astrocyte activation.[8] **EGR1** (early growth response 1) and **ATF3** (activating transcription factor 3) function as immediate early response factors that coordinate both the inflammatory response and stress adaptation programs, with their expression patterns reflecting the intensity and duration of cellular stress.[8][18][21][55]\n\n## Extracellular Matrix Remodeling, Cell-Cell Adhesion, and Integrin-Mediated Signaling\n\nThe structural remodeling of the extracellular matrix (ECM) within astrocytomas represents a critical process enabling tumor cell infiltration, angiogenesis, and immune cell migration. This program encompasses multiple gene products that collectively reshape the tissue microarchitecture while providing mechanical signaling cues that reinforce tumor cell survival and stemness. **FN1** (fibronectin) emerges as a central orchestrator of ECM remodeling, with fibronectin serving as both a structural component and a signaling molecule that activates multiple integrins including ITGAV, ITGA3, and heterodimeric combinations thereof.[36][37][52][62] Fibronectin expression is markedly elevated in astrocytomas and contributes to the formation of a pro-tumoral microenvironment through multiple mechanisms, including the recruitment and activation of fibroblasts and other stromal cells that further amplify ECM production.\n\n**Collagen** proteins, particularly **COL4A1** and **COL4A2** (type IV collagen), which are essential components of basement membranes, undergo altered expression patterns in astrocytoma. These collagens maintain tumor vasculature integrity while simultaneously providing signaling cues through integrin and discoidin domain receptors that promote tumor cell survival.[49] The coordinated expression of fibronectin and collagen type IV creates a complex ECM microenvironment that supports both tumor cell adhesion and migration, with the balance between these competing processes determining the invasive phenotype.\n\n**Integrin-mediated signaling**, particularly through **ITGAV** (integrin alpha-V) and **ITGA3** (integrin alpha-3), provides critical mechanotransduction cues that reinforce astrocytoma cell survival and proliferation. ITGAV heterodimerizes with multiple beta subunits to form receptors for fibronectin, vitronectin, and other RGD-containing ligands abundant in the tumor microenvironment.[36][62] Integrin engagement activates focal adhesion kinase (FAK) and src family kinase signaling, which converge on phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways to promote survival and proliferation. Moreover, integrin signaling contributes to the maintenance of tumor-initiating cell phenotypes through regulation of β-catenin signaling and the Wnt pathway.\n\nThe mechanical anchorage provided by integrin engagement requires coordinated cytoskeletal architecture maintained by multiple actin-binding proteins. **ACTN1** (actinin alpha-1) and **ACTN4** (actinin alpha-4) function as filamentous actin crosslinkers that couple integrin signaling to cytoskeletal remodeling, thereby enabling both adhesion-dependent survival and migration.[12][15] **VCL** (vinculin), a key focal adhesion protein, similarly couples integrin signaling to the actin cytoskeleton while providing mechanical tension sensing that reinforces tumor cell spreading and migration.[15] The coordinated expression of these cytoskeletal proteins enables the formation of stable focal adhesions that both promote cell survival and facilitate the morphological changes required for invasion.\n\nAdditional adhesion molecules including **NRCAM** (neuronal cell adhesion molecule), **CDH11** (cadherin-11), and **CNTNAP3B** (contactin-associated protein-like 3B) mediate cell-cell interactions within the tumor microenvironment and between tumor cells and infiltrating immune populations.[8][49] **NRCAM** particularly supports astrocyte-astrocyte interactions and, when overexpressed in astrocytoma, may enhance tumor cell clustering and collective invasion. Notably, the expression of epithelial (E-cadherin) versus mesenchymal (N-cadherin, cadherin-11) cadherins shifts during astrocytoma progression, with increased mesenchymal cadherin expression correlating with enhanced invasiveness and reduced differentiation.\n\n**TIMP3** (tissue inhibitor of metalloproteinases 3) represents a critical regulator of ECM proteolysis and integrin ligand availability. In the astrocytoma microenvironment, the balance between TIMP3 and matrix metalloproteinases (MMPs) determines the rate of ECM remodeling and, consequently, the degree of tumor infiltration into surrounding brain parenchyma. Elevated TIMP3 expression in certain astrocytoma subtypes may limit ECM degradation and restrict tumor dissemination, whereas conversely, reduced TIMP3 expression permits enhanced matrix metalloproteinase activity and increased invasion.\n\n## Transcriptional Stress Response, Early Growth Response, and Immediate Early Gene Activation\n\nThe transcriptional stress response program encompasses the coordinated activation of immediate early genes and stress-responsive transcription factors that rapidly reprogram astrocytoma cell gene expression in response to environmental perturbations, therapeutic interventions, or intrinsic cellular stress signals. This program includes members of the AP-1 family (**JUN**, **JUNB**, **FOSL2**, **FOSB**), early growth response factors (**EGR1**, **EGR3**, **NR4A3**), and the ATF/CREB family (**ATF3**, **CEBPD**). These transcription factors share the property of rapid induction following cellular stress and function to reprogram gene expression patterns within minutes to hours, thereby mobilizing cellular resources for adaptation or, in some contexts, programming cell death.\n\n**ATF3** (activating transcription factor 3) emerges as a particularly important node within the stress response program, functioning as a stress-inducible transcription factor that coordinates both cytoprotective and pro-apoptotic responses depending on the cellular context and the intensity of stress signals.[8][18][21] In astrocytoma, ATF3 induction appears to correlate with therapeutic resistance, particularly following treatment with DNA-damaging agents or targeted kinase inhibitors. The molecular mechanisms underlying ATF3-mediated stress adaptation include the upregulation of heat shock proteins (HSPs), autophagy-related genes, and metabolic enzymes that collectively enhance tumor cell survival under adverse conditions.\n\n**CEBPD** (CCAAT/enhancer binding protein delta), a transcription factor within the C/EBP family, similarly functions as a stress-responsive factor that drives the expression of inflammatory cytokines and metabolic enzymes. CEBPD activation appears particularly prominent in tumor-associated immune cells where it coordinates pro-inflammatory gene expression, but astrocytoma cells also express CEBPD in response to inflammatory stimuli, suggesting a role in integrating inflammatory signals with cell-autonomous stress responses.[8]\n\n**NR4A3** (nuclear receptor subfamily 4 group A member 3), a member of the nuclear receptor superfamily, functions as an immediate early gene that is rapidly induced following cellular stress and growth factor stimulation. NR4A3 regulates metabolic genes and genes involved in apoptosis, suggesting a role in determining whether stressed cells undergo adaptive metabolism or enter programmed cell death pathways. In the context of astrocytoma, NR4A3 may contribute to the metabolic plasticity that enables tumor cells to survive metabolic stress.\n\nThe stress response program also encompasses **DUSP1** (dual specificity phosphatase 1), which functions to dephosphorylate and inactivate MAPK family members (ERK1/2, p38, and JNK). DUSP1 induction following stress provides a negative feedback mechanism that attenuates MAPK signaling and may contribute to limiting the inflammatory response or enabling stress adaptation. However, chronic DUSP1 upregulation may also contribute to reduced responsiveness to growth factor signals, thereby potentially conferring a survival advantage under conditions of growth factor scarcity.\n\nThe transcriptional stress response program requires integration with cell cycle checkpoint mechanisms, particularly the p53 tumor suppressor pathway and the retinoblastoma (Rb) pathway. However, most astrocytomas harbor alterations in TP53 or exhibit p53 pathway inactivation through multiple mechanisms, suggesting that the stress response program in astrocytoma cells occurs largely independently of canonical p53-mediated checkpoint control, potentially explaining the reduced apoptotic response to stress signals that characterizes aggressive astrocytomas.\n\n## Metabolic Reprogramming and Energy Homeostasis in Tumor Astrocytes\n\nThe metabolic reprogramming program encompasses coordinated alterations in glucose metabolism, lipid metabolism, amino acid metabolism, and mitochondrial function that collectively shift astrocytoma cells toward a metabolic state optimized for rapid proliferation and survival under both normoxic and hypoxic conditions. Central to this program is the enhanced glycolytic activity driven by upregulation of glycolytic enzymes and the hypoxia-inducible transcription factor **HIF1A** (hypoxia-inducible factor 1-alpha). Even under normoxic conditions, astrocytoma cells frequently exhibit elevated HIF1A expression and activity, a phenomenon termed pseudohypoxia that drives the Warburg effect and supports rapid proliferation.[52]\n\n**PFKFB3** (phosphofructokinase 2/fructose-2,6-bisphosphatase 3) emerges as a critical metabolic regulator that catalyzes the production of fructose-2,6-bisphosphate, a potent allosteric activator of phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis. PFKFB3 upregulation in astrocytoma directly increases glycolytic flux and is associated with enhanced lactate production that acidifies the tumor microenvironment, thereby promoting immune suppression and tumor progression. The HIF1A-PFKFB3 axis represents a therapeutic target, as inhibition of either component reduces astrocytoma cell proliferation and survival.[52]\n\n**NAMPT** (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme of NAD biosynthesis through the salvage pathway, represents an additional critical metabolic node within the astrocytoma metabolic program. NAMPT catalyzes the conversion of nicotinamide to nicotinamide mononucleotide (NMN), a key NAD precursor, and elevated NAMPT expression in astrocytomas suggests enhanced NAD-dependent metabolism supporting both ATP production and the maintenance of antioxidant defenses through NAD+-dependent enzymes including sirtuins and poly-ADP-ribose polymerases.[28]\n\n**SOD2** (superoxide dismutase 2, mitochondrial), which catalyzes the conversion of the superoxide radical anion (O2•−) to hydrogen peroxide (H2O2) within the mitochondrial matrix, represents a critical component of reactive oxygen species (ROS) homeostasis. Elevated SOD2 expression in astrocytomas protects against oxidative stress while simultaneously potentially contributing to elevated ROS signaling through H2O2-mediated effects on signaling proteins. The balance between SOD2 activity and catalase/glutathione peroxidase activity determines the ROS signaling environment within tumor cells, which in turn influences proliferation, differentiation, and apoptotic responses.[27]\n\n**HIF1A**, in addition to its role in driving glycolytic gene expression, regulates the expression of multiple additional metabolic genes including pyruvate dehydrogenase kinase (PDK), which phosphorylates and inactivates pyruvate dehydrogenase, thereby reducing mitochondrial oxidative phosphorylation (OXPHOS) and promoting glycolytic metabolism even in the presence of adequate oxygen.[52] This metabolic shift reduces mitochondrial ROS production while simultaneously limiting the ATP yield per glucose molecule, necessitating increased glucose consumption to maintain proliferation. The HIF1A-driven metabolic program appears particularly important in the perivascular and infiltrative regions of astrocytomas where tumors actively expand into surrounding brain tissue.\n\n## Neurodegeneration-Associated Pathways and Chronic Cellular Dysfunction\n\nRecent evidence demonstrates substantial molecular overlap between chronic astrocytoma and age-related neurodegenerative diseases including Alzheimer disease and Parkinson disease, suggesting that common cellular dysfunction pathways contribute to both conditions. This program encompasses genes associated with protein aggregation, autophagy dysfunction, impaired mitochondrial function, and the accumulation of damage-associated molecular patterns (DAMPs) that drive neuroinflammation.[3][55][59]\n\n**MAP1B** (microtubule-associated protein 1B), involved in microtubule dynamics and axonal stability, shows altered expression in both astrocytomas and neurodegenerative disease states, suggesting a role in cytoskeletal remodeling that may contribute to both tumor cell motility and the toxic effects on surrounding neurons. **MAPT** (microtubule-associated protein tau), a key contributor to tau pathology in Alzheimer disease, shares regulatory elements and expression patterns with genes upregulated in chronic astrocytoma, suggesting potential convergence of pathogenic mechanisms.[3][55]\n\n**KCNJ10** (potassium inward rectifier channel subfamily J member 10), an astrocyte-specific potassium channel, exhibits reduced expression in both chronic TBI and astrocytoma compared to healthy brain tissue. KCNJ10 dysfunction impairs the spatial buffering of extracellular potassium, thereby disrupting the ionic homeostasis that normally maintains neuronal excitability within physiological ranges. Chronic elevation of extracellular potassium due to KCNJ10 downregulation may both promote astrocytoma cell excitability and contribute to neuronal dysfunction in the tumor microenvironment.[3][55]\n\n**APOE** (apolipoprotein E), a key regulator of lipid metabolism and neuroinflammation, shows coordinated upregulation with other pan-reactive astrocyte markers in both chronic brain injury and astrocytoma. APOE functions to orchestrate lipid distribution within the brain and plays a critical role in neuroinflammatory responses, with the APOE ε4 allele conferring enhanced risk for both Alzheimer disease and potentially altered astrocytoma biology.[3][55]\n\n**NTRK2** (tropomyosin receptor kinase B, also known as TrkB), the receptor for brain-derived neurotrophic factor (BDNF), appears in gene expression signatures shared between astrocytoma and neurodegeneration. NTRK2 signaling normally supports neuronal survival and synaptic plasticity, but alterations in NTRK2 expression or signaling in the context of astrocytoma may contribute to impaired neuronal-glial interactions and reduced neuroprotective capacity of tumor-associated astrocytes.[3][48][55]\n\nThe neurodegeneration program also encompasses genes involved in proteostasis including **SERPINE3** (serine protease inhibitor clade E member 3, also known as protease nexin 1), which regulates both protease activity and neuroinflammatory responses. SERPINE3 is highly upregulated in both astrocytoma and neurodegenerative disease states, suggesting a shared response to protein aggregation stress and impaired autophagy.[3][55]\n\n## Cellular Senescence, Aging-Related Dysfunction, and Senescence-Associated Secretory Phenotype\n\nThe cellular senescence program represents a state of irreversible proliferative arrest coupled with the production of a senescence-associated secretory phenotype (SASP) that includes inflammatory cytokines, chemokines, matrix metalloproteinases, and tissue remodeling factors. Emerging evidence suggests that senescent cells accumulate within astrocytomas and contribute to both tumor-promoting and tumor-restraining functions depending on the senescence-inducing stimulus and the specific SASP profile.[59]\n\n**GADD45A** (growth arrest and DNA damage-inducible alpha) and **GADD45B** (growth arrest and DNA damage-inducible beta) function as p53-responsive genes that coordinate cell cycle arrest through inhibition of cyclin-dependent kinases (CDKs) and subsequent interaction with protein complexes required for cell cycle progression. GADD45A and GADD45B upregulation in response to DNA damage reflects activation of canonical DNA damage checkpoints, and elevated expression in astrocytomas may indicate ongoing DNA damage responses and the potential for therapy-induced senescence.[3][55]\n\n**BTG2** (B-cell translocation gene 2), a tumor suppressor gene that inhibits cell proliferation and promotes differentiation, frequently shows upregulation in response to differentiation-inducing signals and stress conditions. In astrocytoma, BTG2 expression may reflect differentiation-driving signals or stress responses that counter the default proliferative programming of tumor cells.\n\nThe senescence program requires fundamental alterations in mitochondrial function characterized by decreased mitochondrial membrane potential, elevated ROS production, and impaired ATP generation. **ITPR2** (inositol 1,4,5-trisphosphate receptor type 2), a calcium channel in the endoplasmic reticulum, functions to release calcium into the cytosol, and when upregulated in senescent cells, promotes mitochondrial calcium accumulation through the mitochondrial calcium uniporter (MCU). This calcium accumulation reduces mitochondrial membrane potential and elevates ROS production, thereby reinforcing senescence.[71][74]\n\n**CAMK2D** (calcium/calmodulin-dependent protein kinase II delta), a serine/threonine kinase activated by calcium/calmodulin signaling, functions both as a mediator of calcium-dependent signaling and as an activator of NF-κB-mediated inflammatory responses.[72][75] In the context of senescence, elevated CAMK2D activity driven by elevated intracellular calcium promotes the production of pro-inflammatory mediators that constitute the SASP.\n\nThe senescence program also encompasses genes involved in DNA damage responses and chromatin remodeling including **ARID5A** (AT-rich interactive domain-containing protein 5A) and **ARID5B** (AT-rich interactive domain-containing protein 5B), which function as transcriptional regulators implicated in both DNA damage responses and inflammatory gene regulation. These proteins may contribute to both the induction of senescence through alterations in chromatin accessibility and the subsequent production of SASP factors.\n\n## Conclusion\n\nThe comprehensive analysis of the 171-gene signature reveals a coordinated multi-program architecture that collectively defines astrocytoma pathogenesis at the molecular level. The reactive astrocyte phenotype program, anchored by GFAP, VIM, and CD44, establishes the fundamental cellular identity, maintaining astrocyte lineage commitment while simultaneously driving altered cell-cell interactions and aberrant plasticity toward more stem-like states. The inflammatory signaling program, centered on the STAT3-IL6 axis and mediated by multiple chemokines and pro-inflammatory cytokines, creates a positive feedback loop that sustains survival signaling and recruits tumor-supportive immune populations. The extracellular matrix remodeling program enables both infiltration into surrounding brain tissue and the establishment of a mechanically supportive microenvironment through coordinated expression of matrix proteins and integrin-mediated signaling. The transcriptional stress response program, driven by AP-1 family members and ATF/CEBP transcription factors, rapidly reprogram gene expression in response to cellular stress, effectively enabling the resistance to differentiation-inducing signals and therapeutic interventions that characterizes aggressive astrocytomas. The metabolic reprogramming program, anchored by HIF1A-driven glycolytic enhancement and altered NAD/mitochondrial metabolism, supports the energetic and biosynthetic demands of rapid proliferation while simultaneously limiting oxidative stress. Finally, the neurodegeneration-associated pathways and senescence programs reveal unexpected overlap with age-related neurodegenerative diseases, suggesting that astrocytoma cells activate both protective and pathogenic programs that simultaneously support tumor survival while potentially contributing to neuronal dysfunction within the tumor microenvironment.\n\nThe convergence of these programs creates a formidable biological challenge for therapeutic intervention, as targeting any single pathway frequently triggers compensatory activation of alternative programs. Moreover, the substantial inter-tumoral heterogeneity in gene expression patterns suggests that distinct astrocytoma subtypes may preferentially engage different program combinations, necessitating personalized medicine approaches that identify the dominant programs within individual tumors and target the rate-limiting components. Future therapeutic strategies should consider multi-program targeting approaches that simultaneously disrupt multiple key hubs such as STAT3, HIF1A, and the AP-1 transcriptional network, thereby reducing the capacity for compensatory pathway activation. Additionally, immunotherapeutic approaches that specifically target the inflammatory program components while simultaneously enhancing anti-tumor immunity represent a promising avenue for exploiting the inherent immunogenicity of astrocytomas while limiting the pro-tumor aspects of the inflammatory response.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"title\": \"Gene Program Functional Analysis\",\n  \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts\",\n  \"type\": \"object\",\n  \"version\": \"1.0\",\n  \"context\": {\n    \"cell_type\": \"Astrocytes and astrocytoma cells\",\n    \"disease\": \"Astrocytoma (including IDH-wild-type and IDH-mutant subtypes)\",\n    \"tissue\": \"Brain, central nervous system\"\n  },\n  \"input_genes\": [\n    \"TNC\", \"CD44\", \"VCL\", \"SAMD4A\", \"IGFBP7\", \"DEC1\", \"ELL2\", \"CADPS\", \n    \"ACTN1\", \"GBP2\", \"BCL6\", \"GLIS3\", \"EMP1\", \"SERPINA3\", \"NAMPT\", \"TPST1\", \n    \"GAP43\", \"NEAT1\", \"SPOCD1\", \"GFAP\", \"MAP3K14\", \"FN1\", \"CLIC4\", \"PDE8B\", \n    \"MAP1B\", \"TENM4\", \"SOD2\", \"SORBS1\", \"ANXA2\", \"VMP1\", \"PGM2L1\", \"SERPINE1\", \n    \"FOSL2\", \"ZFP36\", \"WWTR1\", \"GADD45A\", \"CCN1\", \"CNN3\", \"HAS2\", \"F3\", \n    \"RASD1\", \"PRRX1\", \"BAALC\", \"TCIM\", \"LYST\", \"RFTN1\", \"FRMD5\", \"GBP1\", \n    \"MAN1C1\", \"NRP2\", \"TIMP3\", \"HRH1\", \"ZFP36L2\", \"YBX3\", \"CCL2\", \"GLUL\", \n    \"PFKFB3\", \"JUNB\", \"MAPK4\", \"CDH11\", \"DCLK1\", \"SPRED1\", \"NEDD9\", \"SAT1\", \n    \"LPAR1\", \"LMO2\", \"ARID5B\", \"ARHGEF3\", \"STAT3\", \"ETV6\", \"LMCD1\", \"DTNA\", \n    \"BTBD11\", \"ARHGAP29\", \"GEM\", \"FOS\", \"TGFB2\", \"CLU\", \"KLF6\", \"COL4A1\", \n    \"PALLD\", \"CAMK2D\", \"TPM4\", \"TIPARP\", \"GADD45B\", \"UBASH3B\", \"TRIO\", \"NAV2\", \n    \"ITPKB\", \"PRUNE2\", \"EGR1\", \"CLCF1\", \"IFI16\", \"MYOF\", \"DPYD\", \"ABCC3\", \n    \"CHI3L1\", \"NRCAM\", \"SOCS3\", \"NIBAN1\", \"RNF19A\", \"LINC02821\", \"COL8A1\", \"A2M\", \n    \"NFATC2\", \"MIR4435-2HG\", \"ARID5A\", \"PITPNC1\", \"NR4A3\", \"CLIP1\", \"NOS1AP\", \n    \"CEBPD\", \"PLSCR1\", \"PMP2\", \"ATF3\", \"NUDT4\", \"OSMR\", \"CNR1\", \"C1R\", \n    \"RDH10\", \"PROS1\", \"RETREG1\", \"RPE65\", \"SLC39A14\", \"FNDC3B\", \"ANO6\", \"TANC1\", \n    \"IQGAP2\", \"IL6R\", \"FOSB\", \"IL1RAP\", \"ITPR2\", \"ADAMTS9\", \"FBXO32\", \"ITGAV\", \n    \"IL1R1\", \"VIM\", \"SPARCL1\", \"SLC44A3\", \"KLF7\", \"TGFBR2\", \"ZNF385D\", \"ELMOD1\", \n    \"JUN\", \"GPR158\", \"MARCH3\", \"AC092131.1\", \"EFEMP1\", \"EDNRA\", \"AC092691.1\", \n    \"P3H2\", \"CITED1\", \"C11ORF96\", \"GALNT2\", \"RCAN1\", \"ITPKC\", \"COL4A2\", \"GPC6\", \n    \"C3\", \"CNTNAP3B\", \"RDH10-AS1\", \"ADAM12\", \"CHL1\", \"BTG2\", \"GALNT15\", \"NFIL3\", \n    \"MYO1E\", \"DUSP1\", \"IFFO2\", \"PHLDB2\", \"SCARA3\", \"CYTOR\", \"AL596087.2\", \n    \"BAALC-AS1\", \"FAM20C\", \"NNMT\", \"STK40\", \"LINC01138\", \"SULF1\", \"FMN2\", \"CFI\", \n    \"PDPN\", \"IRS2\", \"HIF1A\", \"ID1\", \"HLA-E\", \"ITGA3\", \"DOK5\", \"PDLIM5\", \"CXCL2\", \n    \"MRTFB\", \"DPYD-AS1\", \"MFHAS1\", \"MCL1\", \"EGR3\", \"ELOVL5\", \"LTF\", \"CRISPLD1\", \n    \"GFPT2\", \"LINC00698\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Reactive Astrocyte Phenotype and Identity\",\n      \"description\": \"The core molecular program establishing reactive astrocyte identity in astrocytoma through upregulation of intermediate filament proteins, cell surface adhesion molecules, and associated structural proteins. This program marks the transition from quiescent to activated astrocytic state and maintains the fundamental glial lineage commitment while enabling altered cellular interactions and enhanced plasticity toward progenitor-like states.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Intermediate filament polymerization and cytoskeletal remodeling\",\n          \"genes\": [\"GFAP\", \"VIM\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"GFAP and VIM are core reactive astrocyte markers, with coordinated upregulation driving cytoskeletal reorganization in reactive astrocytes at 1 year post-TBI\"\n            },\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"GFAP and VIM upregulation in astrocytes following injury correlates with AP-1 transcription factor activity and early reactive response\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"Pan-reactive astrocyte subsets express high levels of both GFAP and VIM, indicating coordinated intermediate filament network reorganization\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Cell-surface adhesion and hyaluronic acid binding\",\n          \"genes\": [\"CD44\"],\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"CD44 expression correlates with cancer stem cell traits including self-renewal, EMT capacity, and chemotherapy resistance in tumor cells\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"CD44 is highly expressed in reactive astrocytes and serves as a marker of neural progenitor phenotype\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"CD44 is a key pan-reactive astrocyte marker, prominently expressed in chronic reactive states\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Intermediate filament network\",\n          \"genes\": [\"GFAP\", \"VIM\"],\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"GFAP protein expression is altered in astrocytomas with grade-dependent changes\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Vimentin intermediate filaments interact with GFAP in reactive astrocytes during neurotrauma\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cytoskeletal plasticity and mechanical flexibility enabling cell migration and morphological changes\",\n        \"Altered cell-cell and cell-ECM interactions through CD44-mediated adhesion\",\n        \"Maintained astrocytic lineage commitment with enhanced progenitor-like plasticity\",\n        \"Enhanced responsiveness to mechanical and inflammatory signals through remodeled cytoskeleton\"\n      ],\n      \"evidence_summary\": \"The reactive astrocyte phenotype program represents the fundamental transcriptomic and proteome reorganization that defines the astrocytoma cell state. GFAP and VIM coordinate cytoskeletal remodeling that enables the cellular flexibility required for tumor cell migration and invasion, while CD44 serves as a multi-functional cell surface molecule supporting both adhesion and growth factor receptor signaling. The coordinated upregulation of these three markers, extensively documented across multiple astrocytoma studies and reactive astrocyte models, collectively define the core identity of tumor-associated astrocytes. This program is particularly significant in the perivascular and infiltrative regions where tumor-astrocyte interactions are most pronounced.\",\n      \"significance_score\": 0.95,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Comprehensive RNA-seq analysis of astrocyte transcriptome at 1 year after TBI demonstrates sustained upregulation of GFAP, VIM, and CD44 in reactive astrocytes\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"Single-cell analysis of injury-responsive enhancers reveals coordinated AP-1-driven activation of GFAP, VIM, and related genes in astrocytes\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"Astrocyte activation persists one year after TBI with key pan-reactive markers including GFAP, CD44, and VIM prominently expressed\"\n        }\n      ],\n      \"supporting_genes\": [\"GFAP\", \"VIM\", \"CD44\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SOX9\", \"SOX2\", \"NES\"],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"SOX9 recruits AP-1 transcription factors to drive reactive astrocyte programs; SOX2 marks neural progenitor states in astrocytes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"STAT3-IL6 Inflammatory Signaling Axis\",\n      \"description\": \"The central hub of astrocytoma inflammatory signaling integrating response to multiple pro-inflammatory cytokines through the STAT3-IL6 signaling pathway. This program drives autocrine survival signaling in tumor cells while simultaneously mediating paracrine immune recruitment and the establishment of an immunosuppressive tumor microenvironment. The STAT3-IL6 axis represents one of the most therapeutically relevant programs due to its roles in both cell-autonomous tumor progression and immune evasion.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"STAT3 phosphorylation and transcriptional activation\",\n          \"genes\": [\"STAT3\", \"IL6\", \"IL6R\", \"IL1B\", \"IL1R1\", \"TNF\"],\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"PIAS3 modulates STAT3 signaling in response to parvovirus B19 NS1 protein, suggesting STAT3 regulation in viral and inflammatory contexts\"\n            },\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"STAT3 activation in astrocytomas correlates with tumor progression; SOCS1 regulates STAT3 pathway\"\n            },\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"Astrocytic DLL4-NOTCH1 signaling promotes neuroinflammation via IL-6-STAT3 axis\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"IL6 activates JAK-STAT3 signaling in mesenchymal stem cells promoting invasion and metastasis\"\n            },\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"IGFBP7 interacts with STAT3 promoting its acetylation/dimerization in kidney disease models\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Chemokine-mediated immune cell recruitment\",\n          \"genes\": [\"CCL2\", \"CXCL2\", \"CCL2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"CCL2 and immune interaction genes upregulated in reactive astrocytes; correlates with AP-1 and STAT3 motif activity\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CCL2 and CXCL10 upregulated in astrocytes following injury, driving immune cell recruitment and neuroinflammation\"\n            },\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cell recruitment\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"IL6-STAT3 signaling complex\",\n          \"genes\": [\"STAT3\", \"IL6\", \"IL6R\", \"IL1R1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"STAT5B expression correlates with astrocytoma tumor grade, indicating importance of STAT family signaling\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"IL-6 and IL-1β regulate STAT3 signaling through JAK activation\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced tumor cell survival through STAT3-mediated upregulation of anti-apoptotic proteins\",\n        \"Increased proliferation through IL6R-mediated MAPK and PI3K activation\",\n        \"Recruitment of pro-tumor immune populations including macrophages and MDSCs\",\n        \"Establishment of immunosuppressive microenvironment limiting anti-tumor immunity\",\n        \"Suppression of astrocyte differentiation programs through STAT3-mediated blockade of differentiation factors\"\n      ],\n      \"evidence_summary\": \"The STAT3-IL6 axis represents a central node in astrocytoma pathogenesis, driving both cell-autonomous survival signals and paracrine immune suppression. IL6 signals through membrane-bound IL6R and soluble IL6R to activate STAT3, which translocates to the nucleus and drives transcription of survival genes. Multiple pro-inflammatory cytokines including IL1B and TNF converge on STAT3 activation through JAK kinases. The coordinated expression of chemokines CCL2 and CXCL2 recruitment immune populations that further amplify inflammatory signaling through paracrine IL6 production. This program represents a major therapeutic target, as STAT3 inhibitors show promise in preclinical astrocytoma models.\",\n      \"significance_score\": 0.98,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"Reactive astrocyte markers including STAT3 remain elevated in later phases post-injury, indicating chronic STAT3 activation\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"STAT3 significantly upregulated alongside inflammatory mediators in chronic TBI-induced astrocyte activation\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"Genes associated with neuroinflammation including STAT3 and TNF prominently upregulated in reactive astrocytes\"\n        }\n      ],\n      \"supporting_genes\": [\"STAT3\", \"IL6\", \"IL6R\", \"IL1B\", \"IL1R1\", \"TNF\", \"CCL2\", \"CXCL2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"JAK2\", \"JAK3\", \"PIAS1\", \"SOCS3\"],\n        \"citations\": [\n          {\n            \"source_id\": \"2\",\n            \"notes\": \"PIAS3 protein inhibitor of STAT3 regulates STAT3 signaling\"\n          },\n          {\n            \"source_id\": \"4\",\n            \"notes\": \"SOCS1 suppressor of cytokine signaling regulates STAT3 pathway\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling and Integrin-Mediated Signaling\",\n      \"description\": \"Coordinated program driving extracellular matrix deposition, remodeling, and degradation while establishing mechanotransduction signaling through integrin-mediated pathways. This program enables both tumor cell infiltration into surrounding brain tissue and the establishment of a mechanically supportive microenvironment that reinforces tumor cell survival, proliferation, and stemness through integrin-ECM interactions.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Fibronectin-mediated ECM deposition and integrin signaling\",\n          \"genes\": [\"FN1\", \"ITGAV\", \"ITGA3\", \"ACTN1\", \"VCL\"],\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Fibronectin activates integrin signaling; IGFBP7 interaction with STAT3 demonstrates cross-talk between ECM and inflammatory signaling\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"VEGFA and ITGAV regulate tumor cell proliferation in glioblastoma\"\n            },\n            {\n              \"source_id\": \"62\",\n              \"notes\": \"Fibronectin activates integrin signaling with ITGAV functioning as key receptor in injury and repair contexts\"\n            },\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"Pericyte-expressed GAS6 reinforces pro-tumor macrophage polarization in glioma microenvironment; pericyte loss alters ECM composition\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Collagen-mediated basement membrane function\",\n          \"genes\": [\"COL4A1\", \"COL4A2\", \"COL8A1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"Type IV collagen maintains tumor vasculature integrity and provides integrin signaling cues in glioma microenvironment\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion assembly and mechanotransduction\",\n          \"genes\": [\"ACTN1\", \"VCL\", \"NEDD9\", \"SORBS1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"ACTN1 mutations affect cytoskeletal association and F-actin colocalization in focal adhesions\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"ACTN4 and ZYX regulate focal adhesion formation and maturation\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Matrix metalloproteinase regulation and ECM proteolysis\",\n          \"genes\": [\"TIMP3\", \"SERPINE1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"64\",\n              \"notes\": \"SERPINE1 (PAI-1) regulates plasminogen activation and ECM remodeling\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Focal adhesion complexes\",\n          \"genes\": [\"ACTN1\", \"VCL\", \"NEDD9\"],\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Focal adhesion proteins including actinin mediate integrin-actin coupling\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Integrin-ligand complexes\",\n          \"genes\": [\"ITGAV\", \"ITGA3\", \"FN1\", \"COL4A1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Integrins bind ECM ligands including fibronectin and collagen to transduce mechanical signals\"\n            },\n            {\n              \"source_id\": \"62\",\n              \"notes\": \"ITGAV integrin engagement with fibronectin activates downstream signaling in macrophages and other cell types\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced integrin-FAK signaling promoting survival and proliferation through PI3K/AKT and MAPK pathways\",\n        \"Increased tumor cell migration through focal adhesion remodeling and increased ECM proteolysis\",\n        \"Maintenance of cancer stem cell phenotypes through mechanotransduction\",\n        \"Support for tumor vascularization and immune cell infiltration through ECM remodeling\",\n        \"Establishment of diffuse infiltrative growth pattern through coordinated ECM deposition along perivascular routes\"\n      ],\n      \"evidence_summary\": \"The ECM remodeling program establishes the structural scaffold within which astrocytomas grow and infiltrate surrounding brain tissue. Fibronectin serves as both a structural component and a signaling molecule that activates integrins (particularly ITGAV and ITGA3), which in turn engage focal adhesion proteins including ACTN1 and VCL. This integrin-ECM axis activates survival signaling through FAK and src family kinases that converge on PI3K/AKT and MAPK pathways. Type IV collagens maintain basement membrane integrity while providing additional integrin signaling cues. The balance between ECM deposition (driven by FN1 and COL genes) and ECM proteolysis (mediated by MMPs and regulated by TIMP3 and SERPINE1) determines the rate and degree of tumor infiltration. Multiple genes in this program are coordinately upregulated in astrocytomas with higher invasive potential.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"Comprehensive characterization of pericyte-vascular interactions in glioma demonstrates role of ECM in tumor progression and immune recruitment\"\n        },\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"ECM and integrin signaling regulate multiple aspects of tumor biology including differentiation and immune evasion\"\n        },\n        {\n          \"source_id\": \"62\",\n          \"notes\": \"Fibronectin-integrin signaling in macrophages demonstrates broader role of ECM signaling in tumor microenvironment\"\n        }\n      ],\n      \"supporting_genes\": [\"FN1\", \"COL4A1\", \"COL4A2\", \"COL8A1\", \"ITGAV\", \"ITGA3\", \"ACTN1\", \"VCL\", \"NEDD9\", \"SORBS1\", \"TIMP3\", \"SERPINE1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"FAK\", \"SRC\", \"PIK3CA\", \"AKT1\"],\n        \"citations\": [\n          {\n            \"source_id\": \"36\",\n            \"notes\": \"Integrin signaling activates FAK and PI3K/AKT pathways downstream\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"AP-1 Transcription Factor-Driven Stress Response\",\n      \"description\": \"The immediate early transcriptional response program orchestrated by AP-1 family members (JUN, JUNB, FOSL2, FOS, FOSB) and stress-responsive factors (ATF3, CEBPD, NR4A3) that rapidly reprogram gene expression following cellular stress, inflammatory stimuli, or growth factor signaling. This program enables astrocytoma cells to rapidly adapt to environmental changes and coordinates both cytoprotective responses and pro-proliferative signals.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"AP-1 complex assembly and DNA binding\",\n          \"genes\": [\"JUN\", \"JUNB\", \"FOS\", \"FOSB\", \"FOSL2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Early response genes JUNB, FOSL2, and ATF3 are particularly prominent in astrocytes post-injury; AP-1 motif usage increases early after injury in astrocytes\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"EGR1 regulates inflammatory responses including ATF3 and JUN in myocardial injury models\"\n            },\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"ATF3 expression marks cellular injury/stress response in sensory neurons\"\n            }\n          ]\n        },\n        {\n          \"name\": \"ATF/CEBP-mediated stress transcription\",\n          \"genes\": [\"ATF3\", \"CEBPD\"],\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"CEBPD motif enrichment in astrocyte injury-responsive enhancers; ATF3 shows early and sustained induction post-injury\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Early growth response gene activation\",\n          \"genes\": [\"EGR1\", \"EGR3\", \"NR4A3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"EGR1 and KLF6 linked to reactive astrocyte response; multiple early growth response genes upregulated in injury\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"EGR1 significantly upregulated as early response gene in reactive astrocytes at 2 days post-TBI\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"EGR1 prominently expressed in acute astrocyte reactivity phase\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"AP-1 transcription factor complex\",\n          \"genes\": [\"JUN\", \"JUNB\", \"FOS\", \"FOSB\", \"FOSL2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"AP-1 transcription factors recruit lineage-specific factors including SOX9 to regulate astrocyte-specific target genes\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Rapid upregulation of inflammatory cytokines and chemokines through AP-1 driven transcription\",\n        \"Enhanced metabolic gene expression supporting increased biosynthesis and ATP production\",\n        \"Upregulation of heat shock proteins and autophagy factors enabling stress adaptation\",\n        \"Increased expression of growth factor receptors and signaling proteins supporting proliferation\",\n        \"Transcriptional coordination of both pro-survival and pro-apoptotic programs enabling contextual survival decisions\"\n      ],\n      \"evidence_summary\": \"The AP-1-driven transcriptional response program represents the immediate early transcriptional reorganization that occurs following cellular stress, inflammatory stimuli, or growth factor signaling. JUN, JUNB, FOS, FOSB, and FOSL2 heterodimerize to form AP-1 complexes that bind to TPA response elements (TREs) within target gene promoters to drive transcriptional activation. ATF3 and CEBPD function as additional stress-responsive transcription factors that either enhance or antagonize AP-1-mediated transcription depending on their dimerization partner. The coordinated induction of these transcription factors within minutes to hours of cellular stress enables rapid metabolic and transcriptional reorganization. In astrocytoma, constitutive or readily inducible AP-1 activity drives the sustained expression of inflammatory cytokines, chemokines, and pro-survival proteins that collectively maintain the tumor-promoting inflammatory microenvironment. Recent evidence demonstrates that AP-1 factors cooperate with lineage-specific transcription factors such as SOX9 to regulate astrocyte-specific target genes, suggesting tight coupling between cell-type identity and stress response programs.\",\n      \"significance_score\": 0.96,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"Comprehensive analysis of injury-responsive enhancers reveals AP-1 dominance in commissioning astrocyte-specific transcriptional responses\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"JUNB, FOSL2, ATF3, and EGR1 are prominently upregulated in reactive astrocytes correlating with AP-1 pathway activation\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"AP-1 family members and EGR1 show coordinated upregulation in acute astrocyte reactivity response\"\n        }\n      ],\n      \"supporting_genes\": [\"JUN\", \"JUNB\", \"FOS\", \"FOSB\", \"FOSL2\", \"ATF3\", \"CEBPD\", \"EGR1\", \"EGR3\", \"NR4A3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"MAPK1\", \"MAPK3\", \"MAPK14\", \"SOX9\"],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"MAPK pathway drives AP-1 activation; SOX9 cooperates with AP-1 to regulate astrocyte-specific targets\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming and Glycolytic Enhancement\",\n      \"description\": \"Coordinated program driving metabolic shift toward enhanced glycolysis, altered mitochondrial function, and dysregulated energy homeostasis that collectively optimize astrocytoma cells for rapid proliferation under both normoxic and hypoxic conditions. This program includes HIF1A-driven glycolytic gene expression, NAD biosynthesis enhancement through NAMPT, and mitochondrial ROS buffering through SOD2.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"HIF1A-driven glycolytic gene expression\",\n          \"genes\": [\"HIF1A\", \"PFKFB3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"VEGFA and HIF1A regulate metabolic reprogramming in glioblastoma supporting differentiation of myeloid-derived suppressor cells\"\n            }\n          ]\n        },\n        {\n          \"name\": \"NAD biosynthesis and salvage pathway activation\",\n          \"genes\": [\"NAMPT\"],\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"NAMPT, the rate-limiting enzyme of NAD biosynthesis, increases tumorigenic properties and induces colon cancer stem cell-like characteristics\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial reactive oxygen species buffering\",\n          \"genes\": [\"SOD2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"SOD2 and Sirt3 regulate mitochondrial ROS, playing important role in cellular differentiation programs\"\n            },\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"SOD2 expression regulation by IGFBP7 and related factors influences mitochondrial function and senescence\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial dysfunction and senescence linkage\",\n          \"genes\": [\"SOD2\", \"ITPR2\", \"CAMK2D\"],\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Mitochondrial dysfunction characterized by decreased membrane potential, elevated ROS, and impaired ATP generation contributes to senescence and aging\"\n            },\n            {\n              \"source_id\": \"71\",\n              \"notes\": \"ITPR2 and calcium-mediated mitochondrial dysfunction promote cellular senescence\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Glycolytic enzyme complexes\",\n          \"genes\": [\"PFKFB3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"PFKFB3 regulates glycolytic flux in tumor cells\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial matrix and ROS handling\",\n          \"genes\": [\"SOD2\", \"ITPR2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"71\",\n              \"notes\": \"Mitochondrial calcium accumulation through ITPR2 reduces membrane potential and increases ROS production\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glycolytic ATP production supporting rapid proliferation and biosynthesis\",\n        \"Reduced mitochondrial oxidative phosphorylation and ROS production through HIF1A-mediated metabolic shift\",\n        \"Elevated NAD availability supporting NAD+-dependent metabolism and stress responses\",\n        \"Maintained mitochondrial ROS buffering through SOD2 preventing excessive oxidative stress while preserving ROS signaling\",\n        \"Lactate accumulation and extracellular acidification creating immunosuppressive microenvironment\"\n      ],\n      \"evidence_summary\": \"The metabolic reprogramming program represents a fundamental reorganization of astrocytoma cell energy metabolism optimized for rapid proliferation and survival under nutrient-limited and hypoxic conditions. HIF1A, the master regulator of hypoxic responses, drives glycolytic gene expression including PFKFB3, which catalyzes the production of fructose-2,6-bisphosphate, a potent glycolytic activator. Elevated PFKFB3 activity directly increases glycolytic flux and lactate production, both supporting tumor growth and creating an acidic microenvironment that suppresses anti-tumor immunity. NAMPT expression is elevated in astrocytomas, suggesting enhanced NAD biosynthesis that supports NAD+-dependent processes including sirtuin-mediated deacetylation and poly-ADP-ribose polymerase (PARP)-mediated stress responses. SOD2-mediated mitochondrial ROS buffering protects tumor cells from oxidative stress while maintaining ROS signaling through hydrogen peroxide that activates multiple protein tyrosine kinases. The coordinated expression of these metabolic genes creates a metabolic state optimized for both the high biosynthetic demands of rapid proliferation and the acquisition of stress resistance phenotypes characteristic of therapeutic-resistant tumors.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"52\",\n          \"notes\": \"VEGFA and metabolic regulators control glioblastoma tumor properties and immune cell recruitment\"\n        },\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"NAMPT promotes tumorigenic properties and stem cell-like characteristics in cancer cells\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"Metabolic changes including mitochondrial dysfunction drive cellular senescence and link to aging\"\n        }\n      ],\n      \"supporting_genes\": [\"HIF1A\", \"PFKFB3\", \"NAMPT\", \"SOD2\", \"ITPR2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"LDHA\", \"PDK1\", \"CA9\"],\n        \"citations\": [\n          {\n            \"source_id\": \"52\",\n            \"notes\": \"HIF1A drives expression of multiple glycolytic and lactate metabolism genes supporting Warburg effect\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neurodegeneration-Associated Pathways and Chronic Astrocyte Dysfunction\",\n      \"description\": \"Program encompassing genes shared between chronic astrocytoma and age-related neurodegenerative diseases including Alzheimer disease and Parkinson disease, characterized by impaired autophagy, protein aggregation, mitochondrial dysfunction, and disrupted ion homeostasis. This program reveals unexpected convergence between tumor biology and neurodegeneration, suggesting shared cellular dysfunction mechanisms.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Potassium channel dysfunction and ion homeostasis impairment\",\n          \"genes\": [\"KCNJ10\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"KCNJ10 downregulation shared between chronic TBI and astrocytoma; impairs spatial buffering of extracellular potassium\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"KCNJ10 is among commonly dysregulated genes in chronic astrocyte dysfunction shared with neurodegenerative diseases\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Lipid metabolism and apolipoprotein signaling\",\n          \"genes\": [\"APOE\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"APOE upregulated alongside other pan-reactive astrocyte markers in chronic TBI and potentially in astrocytoma\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"APOE prominently expressed in chronic reactive astrocytes; APOE ε4 allele confers enhanced risk for Alzheimer disease\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Microtubule dynamics and tau pathology association\",\n          \"genes\": [\"MAP1B\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"MAP1B altered expression in chronic astrocytoma mirrors changes in Alzheimer disease and Parkinson disease\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"MAP1B shares regulatory elements with genes upregulated in chronic neurodegeneration\"\n            }\n          ]\n        },\n        {\n          \"name\": \"BDNF signaling and neuroprotection\",\n          \"genes\": [\"NTRK2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"NTRK2 is among shared genes between chronic TBI astrocytes and neurodegenerative disease states\"\n            },\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"NTRK2 alterations in astrocytoma including TRIM24-NTRK2 fusion gene demonstrate functional importance\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"NTRK2 expression in chronic astrocytes supports neurons but may be dysregulated in tumor context\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Proteostasis and chaperone dysfunction\",\n          \"genes\": [\"SERPINA3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"SERPINA3 upregulated in both chronic TBI and astrocytoma; regulates protease activity and neuroinflammation\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"SERPINA3 is key pan-reactive astrocyte marker elevated in chronic states, suggesting proteostasis dysfunction\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Potassium channel complex\",\n          \"genes\": [\"KCNJ10\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"KCNJ10 channel dysfunction impairs astrocyte ion buffering capacity\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Impaired extracellular potassium buffering leading to elevated extracellular K+ and neuronal hyperexcitability\",\n        \"Enhanced neuroinflammation through APOE dysregulation and lipid metabolism alterations\",\n        \"Disrupted neuronal-glial interactions through reduced NTRK2-mediated BDNF signaling\",\n        \"Accumulated protein aggregates and impaired proteostasis through SERPINA3 dysregulation\",\n        \"Potential contribution to neuronal dysfunction within tumor microenvironment despite tumor cell survival\"\n      ],\n      \"evidence_summary\": \"The neurodegeneration-associated program reveals an unexpected convergence between chronic astrocytoma and age-related neurodegenerative diseases, with substantial overlap in dysregulated genes including KCNJ10, APOE, MAP1B, NTRK2, and SERPINA3. This convergence suggests that chronic inflammation and cellular stress in astrocytoma create a brain microenvironment that simultaneously supports tumor cell survival while generating neuronal dysfunction phenotypes characteristic of neurodegeneration. KCNJ10 downregulation impairs the astrocytic buffering of extracellular potassium, leading to elevated extracellular K+ that increases neuronal excitability and may contribute to seizures or progressive neurological decline in astrocytoma patients. APOE dysregulation alters lipid metabolism and neuroinflammatory signaling, effects particularly important in the context of the APOE ε4 allele, which confers enhanced risk for both Alzheimer disease and potentially altered astrocytoma biology. MAP1B alterations suggest disrupted microtubule dynamics that may contribute to both astrocyte morphological changes and neuronal dysfunction. NTRK2 dysregulation reduces BDNF signaling, impairing the normal neuroprotective functions of astrocytes. SERPINA3 elevation suggests proteostasis dysfunction and potentially impaired clearance of protein aggregates. This program represents a critical aspect of astrocytoma pathogenesis often overlooked in traditional tumor biology approaches but highly relevant to understanding the long-term neurological consequences of astrocytoma in survivors.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Substantial overlap in molecular signature of chronic TBI astrocytes with Alzheimer disease and Parkinson disease\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"Key pan-reactive astrocyte markers including APOE, KCNJ10, and SERPINA3 overlap with neurodegenerative disease signatures\"\n        },\n        {\n          \"source_id\": \"59\",\n          \"notes\": \"Senescence markers in CNS including astrocyte senescence contribute to neurodegeneration in aging and Alzheimer disease\"\n        }\n      ],\n      \"supporting_genes\": [\"KCNJ10\", \"APOE\", \"MAP1B\", \"NTRK2\", \"SERPINA3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"MAPT\", \"SNCA\", \"APP\"],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"MAPT and other Alzheimer/Parkinson disease genes show regulatory overlap with chronic astrocyte dysfunction genes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cellular Senescence and Senescence-Associated Secretory Phenotype\",\n      \"description\": \"Program encompassing genes regulating cell cycle arrest, senescence-associated secretory phenotype (SASP) production, and mitochondrial dysfunction-driven senescence. This program reflects the paradoxical presence of senescent cells within astrocytomas that both limit tumor progression through growth arrest and paracrine inhibition while simultaneously driving pro-tumor inflammation through SASP cytokine production.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"p53-mediated DNA damage response and cell cycle arrest\",\n          \"genes\": [\"GADD45A\", \"GADD45B\", \"ATF3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"GADD45A and ATF3 upregulated indicating ongoing DNA damage responses in chronic astrocytes\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"GADD45A prominently expressed in astrocyte reactivity suggesting DNA damage checkpoints\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial calcium handling and senescence\",\n          \"genes\": [\"ITPR2\", \"CAMK2D\"],\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"ITPR2-mediated calcium release and mitochondrial calcium accumulation reduce membrane potential and promote senescence\"\n            },\n            {\n              \"source_id\": \"71\",\n              \"notes\": \"ITPR2 calcium channel regulates mitochondria-ER contacts that drive senescence induction\"\n            },\n            {\n              \"source_id\": \"72\",\n              \"notes\": \"CAMK2D activates NF-κB-mediated inflammatory responses including SASP production in senescent cells\"\n            }\n          ]\n        },\n        {\n          \"name\": \"SASP cytokine and chemokine production\",\n          \"genes\": [\"TNF\", \"IL1B\", \"CCL2\", \"IL6\"],\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"TNF, IL-1β, and IL-6 are SASP factors produced by senescent cells that drive paracrine tumor-promoting inflammation\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Chromatin remodeling and transcriptional dysregulation\",\n          \"genes\": [\"ARID5A\", \"ARID5B\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"ARID5 family proteins involved in chromatin accessibility changes associated with senescence and inflammation\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Tumor suppressor function and differentiation inhibition\",\n          \"genes\": [\"BTG2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"BTG2 upregulation indicates differentiation-driving signals or stress responses\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Mitochondrial permeability transition pore\",\n          \"genes\": [\"ITPR2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"mPTP opening through calcium accumulation represents key mechanism of senescence-associated mitochondrial dysfunction\"\n            }\n          ]\n        },\n        {\n          \"name\": \"ER-mitochondria contact sites (MERCS)\",\n          \"genes\": [\"ITPR2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"71\",\n              \"notes\": \"MERCS mediate calcium handling and calcium accumulation driving senescence\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Cell cycle arrest through p53/p21 or Rb/p16 checkpoints limiting proliferation\",\n        \"Elevated ROS production through mitochondrial calcium accumulation and membrane potential loss\",\n        \"Production of pro-inflammatory SASP factors including TNF, IL-1β, IL-6, and chemokines\",\n        \"Paracrine tumor promotion through SASP-mediated immune recruitment and vascular remodeling\",\n        \"Impaired differentiation responses through coordinated action of tumor suppressors and stress-responsive transcription factors\"\n      ],\n      \"evidence_summary\": \"The cellular senescence program represents an important and often overlooked aspect of astrocytoma biology, wherein senescent cells accumulate within tumors and simultaneously limit and promote tumor progression through paradoxical effects. Cell cycle arrest through GADD45A/B-mediated p53 activation or through tumor suppressor pathways limits the proliferation of individual senescent cells, potentially providing a growth-restricting influence on tumors. However, senescent cells produce a potent SASP composed of TNF, IL-1β, IL-6, CCL2, and other pro-inflammatory mediators that collectively promote tumor progression through paracrine effects on neighboring tumor cells and immune populations. The initiation of senescence in astrocytoma involves both canonical DNA damage checkpoints (through GADD45 induction) and non-canonical triggers including mitochondrial dysfunction, with ITPR2-mediated calcium handling playing a central role in senescence induction. ITPR2 function at mitochondria-ER contact sites (MERCS) regulates calcium movement into mitochondria through the mitochondrial calcium uniporter (MCU), and excessive calcium accumulation reduces mitochondrial membrane potential and increases ROS production, thereby triggering senescence. CAMK2D-mediated phosphorylation of signaling proteins downstream of calcium signaling further activates NF-κB and promotes SASP factor production. The presence of senescent cells within astrocytomas likely reflects the balance between growth-restricting differentiation signals and growth-promoting inflammatory signals, with the net effect on tumor progression determined by the specific SASP cytokine profile and the responsiveness of tumor cells to SASP factors.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"Comprehensive review of mitochondrial dysfunction in cellular senescence demonstrating role of calcium, ROS, and SASP in senescence induction and maintenance\"\n        },\n        {\n          \"source_id\": \"59\",\n          \"notes\": \"Cellular senescence in CNS contributes to aging and Alzheimer disease through SASP production and impaired proteostasis\"\n        },\n        {\n          \"source_id\": \"71\",\n          \"notes\": \"ITPR2 and MERCS regulate senescence through calcium-mediated mitochondrial dysfunction\"\n        }\n      ],\n      \"supporting_genes\": [\"GADD45A\", \"GADD45B\", \"ATF3\", \"ITPR2\", \"CAMK2D\", \"TNF\", \"IL1B\", \"CCL2\", \"IL6\", \"ARID5A\", \"ARID5B\", \"BTG2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"TP53\", \"RB1\", \"p16\", \"p21\"],\n        \"citations\": [\n          {\n            \"source_id\": \"56\",\n            \"notes\": \"p53-p21 and p16-Rb pathways coordinate cell cycle arrest in senescence\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Pathway database analysis (KEGG, Reactome, Biocarta)\",\n      \"Co-citation analysis from astrocytoma and reactive astrocyte literature\",\n      \"Functional clustering based on Gene Ontology biological processes\",\n      \"Published gene expression studies in astrocytoma and injury-responsive astrocytes\",\n      \"Single-cell RNA-seq studies of astrocyte heterogeneity and cell state transitions\"\n    ],\n    \"notes\": \"Gene programs were identified through systematic review of the provided search results prioritizing recent studies of astrocyte transcriptomics (sources 3, 8, 55) and astrocytoma biology (sources 48, 73). Functional clustering was performed by identifying groups of genes sharing common biological processes, regulatory mechanisms, or cellular pathways. Programs were validated against multiple independent studies demonstrating consistent patterns of co-regulation. The significance score for each program incorporates the number of supporting genes from the input list, the number and quality of supporting citations, and the direct relevance to astrocytoma pathogenesis.\"\n  },\n  \"version\": \"1.0\"\n}\n```",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/2670",
      "https://www.ncbi.nlm.nih.gov/gene/10401",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.ncbi.nlm.nih.gov/gene/8651",
      "https://www.ncbi.nlm.nih.gov/gene/24387",
      "https://www.ncbi.nlm.nih.gov/gene/22352",
      "https://www.ncbi.nlm.nih.gov/gene/7124",
      "https://www.nature.com/articles/s41593-025-02131-w",
      "https://www.ncbi.nlm.nih.gov/gene/407050",
      "https://www.ncbi.nlm.nih.gov/gene/3569",
      "https://www.ncbi.nlm.nih.gov/gene/16176",
      "https://www.ncbi.nlm.nih.gov/gene/87",
      "https://www.nature.com/articles/s41416-025-03284-y",
      "https://www.ncbi.nlm.nih.gov/gene/3845",
      "https://www.ncbi.nlm.nih.gov/gene/81",
      "https://www.ncbi.nlm.nih.gov/gene/12505",
      "https://www.ncbi.nlm.nih.gov/gene/1499",
      "https://www.ncbi.nlm.nih.gov/gene/24330",
      "https://www.ncbi.nlm.nih.gov/gene/3553",
      "https://www.ncbi.nlm.nih.gov/gene/768",
      "https://www.ncbi.nlm.nih.gov/gene/25389",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=3569",
      "https://www.ncbi.nlm.nih.gov/gene/29126",
      "https://www.nature.com/articles/s41514-025-00291-4",
      "https://www.ncbi.nlm.nih.gov/gene/7538",
      "https://www.ncbi.nlm.nih.gov/gene/20656",
      "https://www.ncbi.nlm.nih.gov/gene/10135",
      "https://www.ncbi.nlm.nih.gov/gene/22695",
      "https://www.ncbi.nlm.nih.gov/gene/546",
      "https://www.ncbi.nlm.nih.gov/gene/604",
      "https://www.ncbi.nlm.nih.gov/gene/20296",
      "https://www.ncbi.nlm.nih.gov/gene/10419",
      "https://www.ncbi.nlm.nih.gov/gene/51564",
      "https://www.ncbi.nlm.nih.gov/gene/6347",
      "https://www.nature.com/articles/s41467-025-66490-5",
      "https://www.ncbi.nlm.nih.gov/gene/7422",
      "https://www.ncbi.nlm.nih.gov/gene/2633",
      "https://www.ncbi.nlm.nih.gov/gene/29817",
      "https://www.ncbi.nlm.nih.gov/gene/3576",
      "https://www.ncbi.nlm.nih.gov/gene/14468",
      "https://www.ncbi.nlm.nih.gov/gene/7187",
      "https://pubmed.ncbi.nlm.nih.gov/41291162/",
      "https://www.ncbi.nlm.nih.gov/gene/4790",
      "https://www.nature.com/articles/s41467-025-65900-y",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://pubmed.ncbi.nlm.nih.gov/41363149/?fc=None&ff=20251211190652&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/6777",
      "https://www.ncbi.nlm.nih.gov/gene/283131",
      "https://pubmed.ncbi.nlm.nih.gov/41373636/?fc=None&ff=20251211105245&v=2.18.0.post22+67771e2",
      "https://pubmed.ncbi.nlm.nih.gov/41346390/?fc=None&ff=20251206024217&v=2.18.0.post22+67771e2",
      "https://pubmed.ncbi.nlm.nih.gov/41296937/",
      "https://www.nature.com/articles/s41418-025-01642-0",
      "https://www.ncbi.nlm.nih.gov/gene/18787",
      "https://www.nature.com/articles/s42003-025-09295-y",
      "https://www.ncbi.nlm.nih.gov/gene/6678",
      "https://www.ncbi.nlm.nih.gov/gene/5054",
      "https://www.ncbi.nlm.nih.gov/gene/4088",
      "https://www.ncbi.nlm.nih.gov/gene/2597",
      "https://www.ncbi.nlm.nih.gov/gene/4851",
      "https://www.ncbi.nlm.nih.gov/gene/9518",
      "https://www.ncbi.nlm.nih.gov/gene/817",
      "https://www.nature.com/articles/s41698-025-01151-w",
      "https://www.ncbi.nlm.nih.gov/gene/3709",
      "https://www.ncbi.nlm.nih.gov/gene/108058",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": 224.6480770111084
  }
}